- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02526524
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled, Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release In Subjects With Type 2 Diabetes Mellitus
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Alabama
-
Anniston, Alabama, Förenta staterna, 36207
- Pinnacle Research Group, LLC
-
Birmingham, Alabama, Förenta staterna, 35294
- University of Alabama at Birmingham
-
Birmingham, Alabama, Förenta staterna, 35216
- Achieve Clinical Research, LLC
-
Birmingham, Alabama, Förenta staterna, 35209
- Central Alabama Research
-
Tuscumbia, Alabama, Förenta staterna, 35674
- Terence T. Hart, MD
-
-
Arizona
-
Chandler, Arizona, Förenta staterna, 85224
- Radiant Research - Phoenix
-
Glendale, Arizona, Förenta staterna, 85306
- Arrowhead Health Centers
-
Peoria, Arizona, Förenta staterna, 85381
- Holland Center for Family Health, LTD
-
Phoenix, Arizona, Förenta staterna, 85018
- Elite Clinical Studies
-
Phoenix, Arizona, Förenta staterna, 85037
- Thunderbird Internal Medicine - Indian School Rd.
-
Surprise, Arizona, Förenta staterna, 85374
- Clinical Research Institute of Arizona, LLC
-
-
Arkansas
-
Fayetteville, Arkansas, Förenta staterna, 72703
- Summit Clinical Trials Center
-
Searcy, Arkansas, Förenta staterna, 72143
- Searcy Medical Center
-
-
California
-
Escondido, California, Förenta staterna, 92025
- Advanced Metabolic Care & Research Institute (AMCR)
-
Fountain Valley, California, Förenta staterna, 92708
- MD Studies, Inc.
-
Huntington Park, California, Förenta staterna, 90255
- National Research Institute
-
La Jolla, California, Förenta staterna, 92037
- Scripps Whittier Diabetes Institute
-
Lincoln, California, Förenta staterna, 95648
- Clinical Trials Research
-
Long Beach, California, Förenta staterna, 90806
- Collaborative Neuroscience Network, LLC
-
Los Angeles, California, Förenta staterna, 90057
- National Research Institute
-
Montclair, California, Förenta staterna, 91763
- Catalina Research Institute
-
National City, California, Förenta staterna, 91950
- SRSD, Inc. dba Synergy San Diego
-
North Hollywood, California, Förenta staterna, 91606
- Providence Clinical Research
-
Oakland, California, Förenta staterna, 94607
- Pacific Research Partners, LLC
-
Orange, California, Förenta staterna, 92868
- SDS Clinical Trials, Inc.
-
Sacramento, California, Förenta staterna, 95825
- Superior Research LLC
-
Sacramento, California, Förenta staterna, 95823
- Center for Clinical Trials of Sacramento
-
Sacramento, California, Förenta staterna, 95823
- Center for Clinical Trials of Scaramento
-
Santa Ana, California, Förenta staterna, 92705
- Syrentis Clinical Research (formerly Research Across America)
-
Spring Valley, California, Förenta staterna, 91978
- Encompass Clinical Research
-
Tustin, California, Förenta staterna, 92780
- Clinical Trial Investigators
-
Van Nuys, California, Förenta staterna, 91405
- Infosphere Clinical Research
-
-
Colorado
-
Colorado Springs, Colorado, Förenta staterna, 80906
- Colorado Springs Health Partners
-
Denver, Colorado, Förenta staterna, 80209
- Creekside Endocrine Associates
-
-
Florida
-
Brooksville, Florida, Förenta staterna, 34601
- Meridien Research - Brooksville
-
Cooper City, Florida, Förenta staterna, 33024
- ALL Medical Research, LLC
-
Hialeah, Florida, Förenta staterna, 33012
- Neostart Corporation dba AGA Clinical Trials
-
Jacksonville, Florida, Förenta staterna, 32277
- Care Partners Clinical Research
-
Jupiter, Florida, Förenta staterna, 33458
- Health Awareness, Inc.
-
Kissimmee, Florida, Förenta staterna, 34741
- Family Health Care Clinical Studies
-
Lakeland, Florida, Förenta staterna, 33810
- Clinical Research of Central Florida-Lakeland
-
Miami, Florida, Förenta staterna, 33014
- Clinical Pharmacology of Miami, Inc.
-
Miami, Florida, Förenta staterna, 33173
- Tellus Clinical Research, Inc.
-
Miami, Florida, Förenta staterna, 33183
- Internal Research Associates LLC - Breton
-
Orlando, Florida, Förenta staterna, 32801
- Clinical Neuroscience Solutions, Inc. Healthcare Orlando
-
Ormond Beach, Florida, Förenta staterna, 32174
- Ormond Medical Arts Pharmaceutical Research Center
-
Pembroke Pines, Florida, Förenta staterna, 33026
- Private Practice - Andres Patron, DO
-
Port Orange, Florida, Förenta staterna, 32127
- Progressive Medical Research
-
Saint Petersburg, Florida, Förenta staterna, 33709
- Meridien Reserach - St. Petersburg
-
Tampa, Florida, Förenta staterna, 33634
- Meridien Research - Tampa
-
Tampa, Florida, Förenta staterna, 33607
- Clinical Reserch Trials of Florida
-
West Palm Beach, Florida, Förenta staterna, 33401
- Metabolic Research Institute, Inc.
-
-
Illinois
-
Addison, Illinois, Förenta staterna, 60101
- Biofortis, Inc.
-
Aurora, Illinois, Förenta staterna, 60506
- AMR Sakeena Research
-
Chicago, Illinois, Förenta staterna, 60607
- Cedar-Crosse Research Center
-
Evanston, Illinois, Förenta staterna, 60201
- Evanston Premier Healthcare Research LLC
-
-
Indiana
-
Valparaiso, Indiana, Förenta staterna, 46383
- Buynak Clinical Research, PC
-
-
Iowa
-
West Des Moines, Iowa, Förenta staterna, 50266
- The Iowa Clinic; Cardiovascular Services
-
-
Kansas
-
Augusta, Kansas, Förenta staterna, 67010
- Heartland Research Associates, LLC - Augusta
-
Topeka, Kansas, Förenta staterna, 66606
- Cotton-O'Neil Clinical Research Center
-
-
Kentucky
-
Edgewood, Kentucky, Förenta staterna, 41017
- Otrimed
-
Lexington, Kentucky, Förenta staterna, 40503
- Kentucky Diabetes Endocrinology Center
-
Louisville, Kentucky, Förenta staterna, 40213
- Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
-
Paducah, Kentucky, Förenta staterna, 42003
- Four Rivers Clinical Research
-
-
Louisiana
-
Crowley, Louisiana, Förenta staterna, 70526
- Avant Research Associates
-
Lake Charles, Louisiana, Förenta staterna, 70601
- Centex Studies, Inc. - Lake Charles
-
-
Maryland
-
Columbia, Maryland, Förenta staterna, 21045
- Columbia Medical Practice
-
Hyattsville, Maryland, Förenta staterna, 20782
- Medstar Health Research Institute
-
Oxon Hill, Maryland, Förenta staterna, 20745
- MD Medical Research
-
-
Massachusetts
-
Quincy, Massachusetts, Förenta staterna, 02169
- Beacon Clinical Research
-
-
Minnesota
-
Edina, Minnesota, Förenta staterna, 55435
- Radiant Research - Edina
-
-
Mississippi
-
Port Gibson, Mississippi, Förenta staterna, 39150
- Planters Clinic
-
-
Montana
-
Butte, Montana, Förenta staterna, 59701
- Mercury Street Medical Group, PLLC
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68114
- Quality Clinical Research, Inc.
-
Omaha, Nebraska, Förenta staterna, 68134
- Heartland Clinical Research
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89119
- AB Clinical Trials
-
Las Vegas, Nevada, Förenta staterna, 89101
- Alliance Against Diabetes
-
Las Vegas, Nevada, Förenta staterna, 89128
- Palm Medical Research
-
Las Vegas, Nevada, Förenta staterna, 89146
- Ingham Neuroscience Group, LLC
-
-
New Jersey
-
Berlin, New Jersey, Förenta staterna, 08009
- Comprehensive Clinical Research
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87109
- Albuquerque Neuroscience, Inc.
-
Albuquerque, New Mexico, Förenta staterna, 87102
- Albuquerque Clinical Trials
-
-
New York
-
Brooklyn, New York, Förenta staterna, 11235
- NY Scientific
-
Great Neck, New York, Förenta staterna, 11023
- Long Island Gastrointestinal Research Group
-
Hopewell Junction, New York, Förenta staterna, 12533
- Mid-Hudson Medical Research, PLLC
-
Westfield, New York, Förenta staterna, 14787
- Great Lakes Medical Research
-
-
North Carolina
-
Greensboro, North Carolina, Förenta staterna, 27408
- PharmQuest
-
Greensboro, North Carolina, Förenta staterna, 27410
- Triad Clinical Trials LLC
-
Rocky Mount, North Carolina, Förenta staterna, 27804
- PMG Research of Rocky Mount
-
Salisbury, North Carolina, Förenta staterna, 28144
- PMG Research of Salisbury, LLC
-
Wilmington, North Carolina, Förenta staterna, 28401
- PMG Research of Wilmington, LLC
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45242
- New Horizons Clinical Research
-
Cincinnati, Ohio, Förenta staterna, 45219
- Sterling Research Group, Ltd
-
Cincinnati, Ohio, Förenta staterna, 45227
- Metabolic Atherosclerosis Research Center
-
Columbus, Ohio, Förenta staterna, 43214
- Urgent Care Specialists, LLC DBA Hometown Urgent Care and Occupational Health
-
Franklin, Ohio, Förenta staterna, 45005
- Prestige Clinical Research
-
Huber Heights, Ohio, Förenta staterna, 45424
- Hometown Urgent Care and Research - Huber Heights
-
Marion, Ohio, Förenta staterna, 43302
- RAS Health LTD
-
Stow, Ohio, Förenta staterna, 44224
- Summit Reserach Group, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73103
- COR Clinical Research, LLC
-
-
Oregon
-
Eugene, Oregon, Förenta staterna, 97404
- Willamette Valley Clinical Studies
-
-
Pennsylvania
-
Downingtown, Pennsylvania, Förenta staterna, 19335
- Brandywine Clinical Research
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29407
- Medical Research South, LLC
-
Greer, South Carolina, Förenta staterna, 29651
- Mountain View CLinical Research - Greer
-
Mount Pleasant, South Carolina, Förenta staterna, 29464
- PMG of Charleston, LLC
-
Myrtle Beach, South Carolina, Förenta staterna, 29588
- Family Medicine of SayeBrook, LLC
-
Simpsonville, South Carolina, Förenta staterna, 29681
- Hillcrest Clinical Research, LLC
-
Spartanburg, South Carolina, Förenta staterna, 29303
- Spartanburg Medical Research
-
Spartanburg, South Carolina, Förenta staterna, 29301
- Palmetto Proactive Healthcare, LLC
-
Summerville, South Carolina, Förenta staterna, 29485
- Palmetto Clinical Research
-
-
Tennessee
-
Bristol, Tennessee, Förenta staterna, 37620
- PMG Research of Bristol, LC - State
-
Knoxville, Tennessee, Förenta staterna, 37912
- PMG Research of Knoxville
-
Memphis, Tennessee, Förenta staterna, 38119
- Clinical Neuroscience Solutions, Inc. - Memphis
-
Tullahoma, Tennessee, Förenta staterna, 37388
- Trinity Clinical Research
-
-
Texas
-
Austin, Texas, Förenta staterna, 78705
- Central Texas Clinical Research
-
Carrollton, Texas, Förenta staterna, 75007
- Trinity Universal Research Associates, Inc.
-
Dallas, Texas, Förenta staterna, 75230
- Dallas Diabetes and Endocrine Center
-
Dallas, Texas, Förenta staterna, 75231
- Research Institute of Dallas
-
Dallas, Texas, Förenta staterna, 75251
- Galenos Research
-
Houston, Texas, Förenta staterna, 77058
- Centex Studies, Inc.
-
Houston, Texas, Förenta staterna, 77036
- Pioneer Research Solutions, Inc.
-
Houston, Texas, Förenta staterna, 77074
- Clinical Trial Network - Houston
-
Houston, Texas, Förenta staterna, 77074
- Juno Research, LLC-Houston
-
Katy, Texas, Förenta staterna, 77450
- Juno Research, LLC-Katy
-
San Antonio, Texas, Förenta staterna, 78215
- Sun Research Institute
-
San Antonio, Texas, Förenta staterna, 78231
- Victorium Clinical Research
-
San Antonio, Texas, Förenta staterna, 78207
- Texas Diabetes Institute Research Center
-
Shavano Park, Texas, Förenta staterna, 78231
- Consano Clinical Research
-
Sugar Land, Texas, Förenta staterna, 77478
- Southwest Health Associates, P.A.
-
-
Utah
-
Saint George, Utah, Förenta staterna, 84790
- Chrysalis Clinical Research
-
-
Virginia
-
Burke, Virginia, Förenta staterna, 22015
- Burke Internal Medicine & Research
-
Manassas, Virginia, Förenta staterna, 20110
- Manassas Clinical Research Center
-
Richmond, Virginia, Förenta staterna, 23235
- Clinical Research Partners, LLC
-
-
Washington
-
Tacoma, Washington, Förenta staterna, 98405
- Universal Research Group, LLC
-
-
-
-
-
Carolina, Puerto Rico, 00987
- Puerto Rico Renal and Health Research, Inc.
-
Cidra, Puerto Rico, 00736
- Advanced Medical Concepts
-
Manati, Puerto Rico, 00674
- Manati Center for Clinical Reserach Doctor's Center Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Is at least 25 years old at Visit 1 (Screening).
Is male, or is female and meets all of the following criteria:
- Not breastfeeding
- Negative pregnancy test result at Visit 1 (not applicable to post-menopausal or surgically sterile females)
- Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study.
- Body mass index (BMI) 20.0 to 45.0 kg/m² (inclusive) at Visit 1 (Screening).
- Has a physical examination with no clinically significant abnormalities as judged by the investigator.
- Has T2DM and an HbA1c of 7.5% to 10.5%, inclusive, at Visit 1.
- Has an estimated glomerular filtration rate (eGFR) value of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation.
Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Visit 1:
- Thiazolidinedione, sulfonylurea, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors
- Hormone replacement therapy (female subjects) and testosterone (male subjects)
- Oral contraceptives (female subjects)
- Antihypertensive agents
- Lipid-lowering agents
- Thyroid replacement therapy
- Antidepressant agents
- Ability to understand and willingness to adhere to protocol requirements.
Exclusion Criteria:
Has a clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:
- Hepatic disease
- Gastrointestinal disease
- Endocrine disorder (T2DM is allowed)
- Cardiovascular disease
- Central nervous system diseases
- Psychiatric or neurological disorders
- Organ transplantation
- Chronic or acute infection
- Orthostatic hypotension, fainting spells or blackouts
- Allergy or hypersensitivity.
- A history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia within the past year.
- Prior major surgery of any kind within 6 months of Visit 1.
- A history of >3% weight change within 3 months of Visit 1.
- A clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormality, other than that related to T2DM, judged by the investigator to be clinically significant at Visit 1.
- An alanine aminotransferase or aspartate aminotransferase result >2.5 × upper limit of normal (ULN) or a bilirubin result >1.5 × ULN.
- A physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.
Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following excluded medications:
- Metformin within 2 months of Visit 1 (Screening)
- Insulin within 2 weeks of Visit 1 (Screening) or for more than 1 week within 3 months of Visit 1 (Screening)
- Glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter 2 inhibitors within 3 months of Visit 1
- Drugs known to affect body weight, including prescription medications and over-the-counter anti obesity agents within 3 months of Visit 1.
- Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of Visit 1
- Planned use of any drug treatment that affects gastric pH (prescription or over-the-counter), such as H2-receptor antagonists and proton pump inhibitors, after Visit 2 (Week -2), or planned chronic use of any antacids (i.e., more than twice per week) after Visit 2 (Week -2)
- Cationic drugs that are eliminated by renal tubular secretion within 1 week of Visit 1.
- Iodinated contrast dye within 1 week prior to Visit 1.
- Investigational drug within 2 months (or five half-lives of the investigational drug, whichever is greater) of the date of the first dose of randomized study medication.
- Met DR or double-blind matching placebo for Met DR at any time prior to Visit 1 (Screening)
- Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.
- Had a blood transfusion or experienced significant blood loss (i.e., >500 mL), including loss due to blood donation, within 2 months prior to Visit 1 (Screening), or is planning to donate blood during the study.
- Has known immune system based allergies or hypersensitivity to any component of study treatment. A history of gastrointestinal intolerance to metformin is not exclusionary.
- Is employed by Elcelyx Therapeutics, Inc. (that is an employee, contract worker, or designee of the company).
- Has a fasting plasma glucose value >270 mg/dL at Visit 1 (Screening), Visit 2 (Week -2), and an unscheduled visit to be completed within 1 week following Visit 2. The unscheduled visit is to be completed only for subjects with a fasting plasma glucose value >270 mg/dL at Visit 1 and Visit 2.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: 600 mg Met DR qAM
600 mg metformin delayed-release once daily in the morning
|
metformin tabletter med fördröjd frisättning
|
|
Experimentell: 900 mg Met DR qAM
900 mg metformin delayed-release once daily in the morning
|
metformin tabletter med fördröjd frisättning
|
|
Experimentell: 1200 mg Met DR qAM
1200 mg metformin delayed-release once daily in the morning
|
metformin tabletter med fördröjd frisättning
|
|
Experimentell: 1500 mg Met DR qAM
1500 mg metformin delayed-release once daily in the morning
|
metformin tabletter med fördröjd frisättning
|
|
Placebo-jämförare: Placebo-1
placebo match for 600 and 1200 mg Met DR qAM treatment groups
|
|
|
Placebo-jämförare: Placebo-2
placebo match for 900 and 1500 mg Met DR qAM treatment groups
|
|
|
Aktiv komparator: 2000 mg Met IR
1000 mg metformin immediate-release twice daily
|
metformin immediate-release tablets
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change in HbA1c (%) at 16 Weeks
Tidsram: Baseline and 16 weeks after the first dose of study medication
|
Baseline and 16 weeks after the first dose of study medication
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Juan P Frias, MD, National Research Institute - Wilshire
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- LCRM112
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .